null

null

null

null

null

null

null

null

null

Minimal debt; primarily equity-financed clinical-stage biotech with ~$30-50M cash runway; near-zero leverage ratio

Negligible direct debt interest exposure; rising rates compress equity valuations and increase cost of future capital raises

High intensity; OPEC+ supply decisions and Russia-Ukraine conflict drive price volatility.

API synthesis dependency on contract manufacturers (likely European/Asian CMOs); levosimendan API sourcing from Orion Corporation (Finland)

No material international revenue; USD-denominated operations; minimal sovereign currency devaluation exposure currently

Virtually 100% US-based operations; no significant foreign revenue markets; currency devaluation risk near-null

High intensity; commodities: Crude Oil, Natural Gas, Coal, Refined Petroleum Products, Uranium, Steel (equipment); geopolitical: OPEC+ supply decisions and Russia-Ukraine conflict drive price volatility.

Orion Corporation supplies levosimendan API; single-source dependency likely exceeds 30% operational input; non-substitutable in near term

Clinical-stage pharma; no cloud infrastructure dependency for revenue generation; minimal disruption risk from cloud termination

Pre-commercial biotech; cloud used for administrative/data purposes only; R&D continuity minimally affected by provider switch

Low API/platform coupling risk; no SaaS dependencies; clinical data systems (EDC) could be migrated within 60-90 days

Revenue model is pharmaceutical product sales; no Howey Test applicability; equity investment risk is standard securities framework

High

Limited GDPR/CCPA exposure; clinical trial patient data subject to HIPAA/ICH GCP; EU trial data requires standard data transfer agreements

Low antitrust risk; single-product niche (levosimendan for PH-HFpEF); no market dominance; orphan-like indication

High burden; regimes: EPA, FERC, DOE, CFTC, OSHA, SEC; Accelerating emissions mandates and methane rules threaten capex economics.

0% recurring revenue currently; pre-revenue clinical stage; future revenue will be transactional pharmaceutical product sales

Future monetization via branded drug sales (levosimendan/Tenaxia) to hospitals/institutions if FDA approved

Pricing not yet established; levosimendan comparables suggest $5,000-$15,000 per treatment course; hospital formulary negotiation required

Moderate-to-high potential pricing power if approved for rare/underserved indication; payer pushback risk remains significant

Pharmaceutical gross margins targeted at 70-85% at commercial scale, contingent on CMO contract terms and API costs

No free-rider risk; prescription pharmaceutical; no recurring subscription model applicable

Revenue growth will require commercial headcount build (sales force); growth is headcount-linear at launch phase for specialty pharma

Marginal cost of revenue growth is moderate; incremental manufacturing variable cost low but commercial infrastructure build is fixed-cost heavy

No franchise network; not applicable to this business model

At 10x scale, CAC dominated by specialty sales force and KOL engagement costs; hospital formulary pull-through economics improve with scale

No network effects present; pharmaceutical adoption driven by clinical evidence and physician relationships, not user network density

AI displacement risk low; clinical development and regulatory affairs are human-intensive; AI could reduce some R&D costs marginally

Moderate recession resistance; cardiac/pulmonary therapies are medically necessary but hospital budget cuts could delay formulary adoption

Cardiologists and pulmonologists treating heart failure with preserved ejection fraction (HFpEF) with pulmonary hypertension

Hospital systems and specialty infusion centers; no single customer concentration risk at commercial stage

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "19-0000 Life, Physical, and Social Science Occupations", "23-0000 Legal Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "53-0000 Transportation and Material Moving Occupations"]

0.33 (HIL — ~33% of characteristic roles agent-automatable)

Capital allocated almost entirely to clinical trials (Phase 3 LEVEL) and regulatory activities; no legacy infrastructure reallocation needed

0000034956

TENX